

# Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults

De Crescenzo F., Ziganshina L., Yudina E., Kaplan Y., Ciabattini M., Wei Y., Hoyle C.  
*Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia*

---

## Abstract

© 2018 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of noradrenaline reuptake inhibitors (NRIs) compared with placebo or no treatment, or any active pharmacological control for treating attention deficit hyperactivity disorder (ADHD) in adults.

<http://dx.doi.org/10.1002/14651858.CD013044>

---

## References

- [1] Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. *JAMA Psychiatry* 2016;73(7):713-20. [DOI: 10.1001/jamapsychiatry.2016.0465; PMC5475268; PUBMED: 27192174]
- [2] Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. *Biological Psychiatry* 2005;57(11):1377-84. [DOI: 10.1016/j.biopsych.2004.08.019; PUBMED: 15950011]
- [3] Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. *Journal of American Academy of Child and Adolescent Psychiatry* 2012;51(4):356-67. [DOI: 10.1016/j.jaac.2012.01.008; PUBMED: 22449642]
- [4] Asherson P, Adamou M, Bolea B, Muller U, Morua SD, Pitts M, et al. Is ADHD a valid diagnosis in adults? Yes. *BMJ* 2010;340:c549. [DOI: 10.1136/bmj.c549; 20348184]
- [5] Asherson P, Young AH, Eich-Höchli D, Moran P, Porsdal V, Deberdt W. Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. *Current Medical Research and Opinion* 2014;30(8):1657-72. [DOI: 10.1185/03007995.2014.915800; PUBMED: 24804976]
- [6] Bangs ME, Jin L, Zhang S, Desai D, Allen AJ, Read HA, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. *Drug Safety* 2008;31(4):345-54. [PUBMED: 18366245]
- [7] Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. *Journal of Child and Adolescent Psychopharmacology* 2014;24(8):426-34. [DOI: 10.1089/cap.2014.0005; PMC4202998]
- [8] Barkley RA. International consensus statement on ADHD. *Clinical Child and Family Psychology Review* 2002;5(2):89-111. [PUBMED: 12093014]
- [9] Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. *Biological Psychiatry* 1999;46(9):1234-42. [PUBMED: 10560028]
- [10] Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, et al. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. *Evidence-Based Medicine* 2017;22(4):143-7. [DOI: 10.1136/ebmed-2017-110716; PMC5537554; PUBMED: 28705922]
- [11] Boesen K, Danborg PB, Gøtzsche PC, Jørgensen KJ. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database of Systematic Reviews* 2017, Issue 11. [DOI: 10.1002/14651858.CD012857]

- [12] Bron TI, Bijlenga D, Verduijn J, Penninx BW, Beekman AT, Kooij JJ. Prevalence of ADHD symptoms across clinical stages of major depressive disorder. *Journal of Affective Disorders* 2016;197:29-35. [DOI: 10.1016/j.jad.2016.02.053; PUBMED: 26970265]
- [13] Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. *Journal of Psychopharmacology* 2016;30(5):444-58. [DOI: 10.1177/0269881116636105; PUBMED: 27005307]
- [14] Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. *Neuropsychopharmacology* 2002;27(5):699-711. [DOI: 10.1016/S0893-133X(02)00346-9; PUBMED: 12431845]
- [15] Camporeale A, Day KA, Ruff D, Arsenault J, Williams D, Kelsey DK. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. *Drug Safety* 2013;36(8):663-71. [DOI: 10.1007/s40264-013-0074-2; PUBMED: 23775507]
- [16] Camporeale A, Porsdal V, De Bruyckere K, Tanaka Y, Upadhyaya H, Deix C, et al. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. *Journal of Psychopharmacology* 2015;29(1):3-14. [DOI: 10.1177/0269881114560183; PUBMED: 25424623]
- [17] Casadei G, Cartabia M, Reale L, Costantino MA, Bonati M, Lombardy ADHD Group. Italian regional health service costs for diagnosis and 1-year treatment of ADHD in children and adolescents. *International Journal of Mental Health Systems* 2017;11:33. [DOI: 10.1186/s13033-017-0140-8; PMC5410029; PUBMED: 28465719]
- [18] Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database of Systematic Reviews* 2011, Issue 6. [DOI: 10.1002/14651858.CD007813.pub2; PUBMED: 21678370]
- [19] Caye A, Rocha TB, Anselmi L, Murray J, Menezes AM, Barros FC, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. *JAMA Psychiatry* 2016;73(7):705-12. [DOI: 10.1001/jamapsychiatry.2016.0383; PUBMED: 27192050]
- [20] Chamberlain SR, Robbins TW. Noradrenergic modulation of cognition: therapeutic implications. *Journal of Psychopharmacology* 2013;27(8):694-718. [DOI: 10.1177/0269881113480988; PUBMED: 23518815]
- [21] Chiarenza GA, Chabot R, Isenhardt R, Montaldi L, Chiarenza MP, Torto MG, et al. The quantified EEG characteristics of responders and non-responders to long-term treatment with atomoxetine in children with attention deficit hyperactivity disorders. *International Journal of Psychophysiology* 2016;104:44-52. [DOI: 10.1016/j.ijpsycho.2016.04.004; PUBMED: 27108364]
- [22] Goldacre B, Drysdale H, Powell-Smith A, Dale A, Milosevic I, Slade E, et al. The COMPare Trials Project. [www.COMPare-trials.org](http://www.COMPare-trials.org) (accessed prior to 26 March 2018).
- [23] Conners CK, Erhardt D, Sparrow E. *Conners Adult ADHD Rating Scales (CAARS): Technical Manual*. North Tonawanda (NY): Multi-Health Systems Inc., 1999.
- [24] Cortese S, Moreira-Maia CR, St Fleur D, Morcillo-Peñalver C, Rohde LA, Faraone SV. Association between ADHD and obesity: a systematic review and meta-analysis. *The American Journal of Psychiatry* 2016;173(1):34-43. [DOI: 10.1176/appi.ajp.2015.15020266; PUBMED: 26315982]
- [25] Veritas Health Innovation. *Covidence*. Melbourne, Australia: Veritas Health Innovation, 2017.
- [26] Cox DJ, Moore M, Burket R, Merkel RL, Mikami AY, Kovatchev B. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology* 2008;18(1):1-10. [DOI: 10.1089/cap.2006.0141; PUBMED: 18294083]
- [27] Cunill R, Castells X, Tobias A, Capellà D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoepidemiology and Drug Safety* 2013;22(9):961-9. [DOI: 10.1002/pds.3473; PUBMED: 23813665]
- [28] De Crescenzo F, Cortese S, Adamo N, Janiri L. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. *Evidence-Based Mental Health* 2017;20(1):4-11. [DOI: 10.1136/eb-2016-102415; PUBMED: 27993933]
- [29] Deeks JJ, Higgins JP, Altman DG, editor(s), Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- [30] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;7(3):177-88. [PUBMED: 3802833]
- [31] American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th Edition. Washington (DC): American Psychiatric Association, 2013.

- [32] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington (DC): American Psychiatric Association, 1987.
- [33] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Association, 2000.
- [34] Pfizer. Package leaflet information for the user. Edronax® 4 mg tablets. [www.medicines.org.uk/emc/files/pil.1578.pdf?filename=PIL.1578.pdf](http://www.medicines.org.uk/emc/files/pil.1578.pdf?filename=PIL.1578.pdf) (accessed prior to 26 March 2018).
- [35] Edvinsson D, Ekselius L. Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adults. *European Archives of Psychiatry and Clinical Neuroscience* 2018; Vol. 268, issue 4:337-47. [DOI: 10.1007/s00406-017-0850-6; PMC5956008; PUBMED: 29143159]
- [36] Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. *Biopharmaceutics and Drug Disposition* 1995;16(6):443-60. [PUBMED: 7579027]
- [37] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34. [PMC2127453; PUBMED: 9310563]
- [38] Eli Lilly USA. Strattera. Highlights of prescribing information (updated 6 April 2015). [www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/021411s046lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021411s046lbl.pdf) (accessed 22 April 2018).
- [39] Eli Lilly Canada. Product Monograph: Strattera® (atomoxetine capsules) 10, 18, 25, 40, 60, 80 and 100 mg. Selective norepinephrine reuptake inhibitor for attention-deficit/hyperactivity disorder (ADHD). [www.lilly.ca/en/pdf/product-monograph/16\\_strattera-pm\\_1oct2015.pdf](http://www.lilly.ca/en/pdf/product-monograph/16_strattera-pm_1oct2015.pdf) (accessed prior to 10 May 2018).
- [40] European Medicines Agency (EMA). European Medicines Agency decision P/0095/2013. [www.ema.europa.eu/docs/en\\_GB/document\\_library/PIP\\_decision/WC500143723.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500143723.pdf) (accessed 11 February 2017).
- [41] Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. *BMJ* 2010;341:c4737. [DOI: 10.1136/bmj.c4737; PMC2954275; PUBMED: 20940209]
- [42] Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychological Medicine* 2006;36(2):159-65. [DOI: 10.1017/S003329170500471X; PUBMED: 16420712]
- [43] Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *The Journal of Clinical Psychiatry* 2010;71(6):754-63. [DOI: 10.4088/JCP.08m04902pur; PUBMED: 20051220]
- [44] Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. *Nature Reviews: Disease Primers* 2015;1:15020. [DOI: 10.1038/nrdp.2015.20; PUBMED: PMID: 27189265]
- [45] Food, Drug Administration (FDA). Strattera® (atomoxetine HCl). [www.accessdata.fda.gov/drugsatfda\\_docs/label/2007/021411s004s012s013s015s021lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf) (accessed 17 December 2017).
- [46] Food, Drug Administration (FDA) Drug Safety Communication. Communication about an ongoing safety review of stimulant medications used in children with attention-deficit/hyperactivity disorder (ADHD). [www.fda.gov/Drugs/DrugSafety/ucm277770.htm](http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm) (accessed 22 April 2018).
- [47] Food, Drug Administration (FDA). Guidance for industry. Enrichment strategies for clinical trials to support Approval of human drugs and biological products. Draft guidance. [www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf) (accessed 29 January 2017).
- [48] Firkusny L, Gleiter CH. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. *British Journal of Clinical Pharmacology* 1994;37(4):383-8. [PMC1364740; PUBMED: 8018460]
- [49] Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. *Clinical Pharmacokinetics* 2000;39(6):413-27. [DOI: 10.2165/00003088-200039060-00003; PUBMED: 11192474 ]
- [50] Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. *Nordic Journal of Psychiatry* 2015;69(4):241-8. [DOI: 10.3109/08039488.2014.972975; PUBMED: 25415763]
- [51] Schünemann H, Broek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of the evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from [gdt.guidelinedevelopment.org/app/handbook/handbook.html](http://gdt.guidelinedevelopment.org/app/handbook/handbook.html).
- [52] McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 26 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

- [53] Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. *Neuropharmacology* 2009;57(7-8):608-18. [DOI: 10.1016/j.neuropharm.2009.08.020; PUBMED: 19761781]
- [54] Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs* 2017;31(3):199-215. [DOI: 10.1007/s40263-017-0410-7; PMC5336546; PUBMED: 28236285]
- [55] Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- [56] Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- [57] Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- [58] Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- [59] World Health Organization (WHO). *The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines*. Geneva (CH): WHO, 1992.
- [60] World Health Organization (WHO). *The ICD-9 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines*. Geneva (CH): WHO, 1978.
- [61] International Conference on Harmonisation (ICH) Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceutical human use. ICH harmonised tripartite guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D (current step 4 version). [www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E2D/Step4/E2D\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf) (accessed 22 April 2018).
- [62] International Narcotics Control Board. Report of the International Narcotics Control Board for 1995. [www.incb.org/documents/Publications/AnnualReports/AR1995/AR\\_1995\\_E.pdf](http://www.incb.org/documents/Publications/AnnualReports/AR1995/AR_1995_E.pdf) (accessed 13 February 2017).
- [63] International Narcotics Control Board. Report of the International Narcotics Control Board for 2014. [www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR\\_2014.pdf](http://www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR_2014.pdf) (accessed 13 February 2017).
- [64] Jamkhande PG, Khawaja A. Role of norepinephrine reuptake inhibitors in attention deficit hyperactivity disorder: a mechanism-based short review. *International Journal of Nutrition, Pharmacology, Neurological Diseases* 2016;6(4):146-51. [DOI: 10.4103/2231-0738.191660]
- [65] Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. *Journal of the American Academy of Child and Adolescent Psychiatry* 2007;46(8):989-1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478]
- [66] Jensen CM, Amdisen BL, Jørgensen KJ, Arnfred SM. Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. *Attention Deficit and Hyperactivity Disorders* 2016;8(1):3-11. [DOI: 10.1007/s12402-016-0188-3; PUBMED: 26801998]
- [67] Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. *BMC Psychiatry* 2017;17(1):302. [DOI: 10.1186/s12888-017-1463-3; PMC5567978; PUBMED: 28830387]
- [68] Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;340:c365. [DOI: 10.1136/bmj.c365; PUBMED: 20156912]
- [69] Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. *Archives of General Psychiatry* 2012;69(12):1295-303. [DOI: 10.1001/archgenpsychiatry.2012.271; PMC3597443; PUBMED: 23070149]
- [70] Kolla NJ, van der Maas M, Toplak ME, Erickson PG, Mann RE, Seeley J, et al. Adult attention deficit hyperactivity disorder symptom profiles and concurrent problems with alcohol and cannabis: sex differences in a representative, population survey. *BMC Psychiatry* 2016;16:50. [DOI: 10.1186/s12888-016-0746-4; PMC4769555; PUBMED: 26920911]
- [71] Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. *European Child & Adolescent Psychiatry* 2014;23(7):587-98. [DOI: 10.1007/s00787-013-0477-8; PMC4077218; PUBMED: 24166532]
- [72] Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

- [73] Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. *The Australian and New Zealand Journal of Psychiatry* 2009;43(2):101-8. [DOI: 10.1080/00048670802607238; PUBMED: 19153917]
- [74] Lieshout M, Luman M, Twisk JWR, Faraone SV, Heslenfeld DJ, Hartman CA, et al. Neurocognitive predictors of ADHD outcome: a 6-year follow-up study. *Journal of Abnormal Child Psychology* 2017;45(2):261-72. [DOI: 10.1007/s10802-016-0175-3; PMC5241361; PUBMED: 27395390]
- [75] Lopez R, Dauvilliers Y, Jaussent I, Billieux J, Bayard S. A multidimensional approach of impulsivity in adult attention deficit hyperactivity disorder. *Psychiatry Research* 2015;227(2-3):290-5. [DOI: 10.1016/j.psychres.2015.03.023; PUBMED: 25895489]
- [76] Mannuzza S, Klein RG, Klein DF, Bessler A, ShROUT P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. *The American Journal of Psychiatry* 2002;159(11):1882-8. [DOI: 10.1176/appi.ajp.159.11.1882; PUBMED: 12411223]
- [77] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute* 1959;22(4):719-48. [PUBMED: 13655060]
- [78] McDonagh MS, Peterson K, Thakurta S, Low A. Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. Final Update 4 Report. Portland (OR): Oregon Health & Science University, 2011. [PUBMED: PMID: 22420008]
- [79] Meinzer MC, Lewinsohn PM, Pettit JW, Seeley JR, Gau JM, Chronis-Tuscano A, et al. Attention-deficit/hyperactivity disorder in adolescence predicts onset of major depressive disorder through early adulthood. *Depression and Anxiety* 2013;30(6):546-53. [DOI: 10.1002/da.22082; PMC3788356; PUBMED: 23424020]
- [80] Mental Health Daily. Strattera (atomoxetine) withdrawal symptoms + duration. [mentalhealthdaily.com/2014/04/26/strattera-atomoxetine-withdrawal-symptoms-duration/](http://mentalhealthdaily.com/2014/04/26/strattera-atomoxetine-withdrawal-symptoms-duration/) (accessed 29 January 2017).
- [81] Meyer BJ, Byrne MK, Collier C, Parletta N, Crawford D, Winberg PC, et al. Baseline omega-3 index correlates with aggressive and attention deficit disorder behaviours in adult prisoners. *PLoS One* 2015;10(3):e0120220. [DOI: 10.1371/journal.pone.0120220; PMC4368577; PUBMED: 25793501]
- [82] Medicines and Healthcare products Regulatory Agency (MHRA). MHRA UK Public Assessment Report. Reboxetine: a review of the benefits and risks, September 2011. [www.mhra.gov.uk/home/groups/s-par/documents/websitesresources/con129107.pdf](http://www.mhra.gov.uk/home/groups/s-par/documents/websitesresources/con129107.pdf) (accessed 17 December 2017).
- [83] Mick E, Faraone SV, Spencer T, Zhang HF, Biederman J. Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD. *Journal of Attention Disorders* 2008;11(4):504-9. [DOI: 10.1177/1087054707308468; PUBMED: 17934183]
- [84] Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. *The American Journal of Psychiatry* 2015;172(10):967-77. [DOI: 10.1176/appi.ajp.2015.14101266; PMC4591104; PUBMED: 25998281]
- [85] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine* 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072]
- [86] Molina BSG, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. *Journal of the American Academy of Child and Adolescent Psychiatry* 2007;46(8):1028-40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481]
- [87] Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. *Journal of the American Academy of Child and Adolescent Psychiatry* 2009;48(5):484-500. [DOI: 10.1097/CHI.0b013e31819c23d0; NCT00000388; PMC3063150; PUBMED: 19318991]
- [88] Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. *BMJ* 2010;340:c547. [DOI: 10.1136/bmj.c547; PUBMED: 20348183]
- [89] Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. *PLoS One* 2010;5(12):e15337. [DOI: 10.1371/journal.pone.0015337; 21179515; PMC3002271]
- [90] Mylan Pharmaceuticals. Maprotiline hydrochloride tablets, USP: 25 mg, 50 mg and 75 mg. [www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/072285s021lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072285s021lbl.pdf) (accessed 1 June 2018).
- [91] Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. *The International Journal of Neuropsychopharmacology* 2009;12(8):1137-47. [DOI: 10.1017/S1461145709990198; PUBMED: 19580697]
- [92] NCT02633527. Efficacy and safety of SPN-812 ER in children with ADHD. [clinicaltrials.gov/ct2/show/NCT02633527](http://clinicaltrials.gov/ct2/show/NCT02633527) (first received 17 December 2015).

- [93] National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. [www.nice.org.uk/guidance/NG87](http://www.nice.org.uk/guidance/NG87) (accessed 12 April 2016).
- [94] National Institutes of Health (NIH). Diagnosis and treatment of attention deficit hyperactivity disorder. [consensus.nih.gov/1998/1998attentiondeficithyperactivitydisorder110html.htm](http://consensus.nih.gov/1998/1998attentiondeficithyperactivitydisorder110html.htm) (accessed 17 December 2017). [PUBMED: 10868163]
- [95] Paris J, Bhat V, Thombs B. Is adult attention-deficit hyperactivity disorder being overdiagnosed?. *Canadian Journal of Psychiatry* 2015;60(7):324-8. [DOI: 10.1177/070674371506000705; PUBMED: PMID: 26175391 PMCID: PMC4500182]
- [96] Pellizzoni C, Poggesi I, Jørgensen NP, Edwards DM, Paus E, Strolin Benedetti M. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. *Biopharmaceutics & Drug Disposition* 1996 Oct;17(7):623-33. [DOI: 10.1002/(SICI)1099-081X(199610)17:7<623::AID-BDD978>3.0.CO;2-S; PUBMED: PMID: 8894119]
- [97] Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. *Psychopharmacology* 2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4; PUBMED: PMID: 18026719]
- [98] Philipsen A, Jans T, Graf E, Matthies S, Borel P, Colla M, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: A randomized clinical trial [Supplemental 1: Trial Protocol]. *JAMA Psychiatry* 2015;72(12):1199-210. [DOI: 10.1001/jamapsychiatry.2015.2146; isrcn.org Identifier: ISRCTN54096201; PUBMED: PMID: 26536057]
- [99] Pingault JB, Cote SM, Galera C, Genolini C, Falissard B, Vitaro F, et al. Childhood trajectories of inattention, hyperactivity and oppositional behaviors and prediction of substance abuse/dependence: a 15-year longitudinal population-based study. *Molecular Psychiatry* 2013 Jul;18(7):806-12. [DOI: 10.1038/mp.2012.87; PMC3954095; PUBMED: 22733124]
- [100] Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry* 1989;28(6):882-7. [DOI: 10.1097/00004583-198911000-00012; PUBMED: 2808258]
- [101] Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. *International Journal of Epidemiology* 2014;43(2):434-42. [DOI: 10.1093/ije/dyt261; PUBMED: PMID: 24464188]
- [102] Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *Journal of Child Psychology and Psychiatry, and Allied Disciplines* 2015 Mar;56(3):345-65. [DOI: 10.1111/jcpp.12381; PUBMED: 25649325]
- [103] PubChem. Compound Summary for CID 5666: viloxazine. [pubchem.ncbi.nlm.nih.gov/compound/5666#section=Top](http://pubchem.ncbi.nlm.nih.gov/compound/5666#section=Top) (accessed 1 June 2018).
- [104] Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database of Systematic Reviews* 2016, Issue 2. [DOI: 10.1002/14651858.CD009996.pub2]
- [105] Renoux C, Shin JY, Dell'Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. *British Journal of Clinical Pharmacology* 2016;82(3):858-68. [DOI: 10.1111/bcp.13000; PMC5338115; PUBMED: 27145886]
- [106] Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- [107] Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. *Drug Metabolism and Disposition* 2002;30(3):319-23. [PUBMED: 11854152]
- [108] Rohatgi. WebPlotDigitizer. Version 4.1. Austin (TX): Rohatgi, 2018.
- [109] Roszdravnadzor. Atomoxetine. [grls.rosminzdrav.ru/grls.aspx?s=](http://grls.rosminzdrav.ru/grls.aspx?s=) (accessed 22 April 2018).
- [110] Rucklidge JJ, Frampton CM, Gorman B, Boggis A. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. *British Journal of Psychiatry* 2014;204:306-15. [DOI: 10.1192/bjp.bp.113.132126; PUBMED: 24482441]
- [111] Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. *Drug Metabolism and Disposition* 2003;31(1):98-107. [PUBMED: 12485958]
- [112] Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. *Clinical Pharmacokinetics* 2005;44(6):571-90. [DOI: 10.2165/00003088-200544060-00002; PUBMED: 15910008]
- [113] Scates AC, Doraiswamy PM. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. *The Annals of Pharmacotherapy* 2000;34(11):1302-12. [DOI: 10.1345/aph.19335; PUBMED: 11098346]

- [114] Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- [115] Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *British Journal of Psychiatry* 2009;194(3):204-11. [DOI: 10.1192/bjp.bp.107.048827; PUBMED: 19252145]
- [116] Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). *European Archives of Psychiatry and Clinical Neuroscience* 2006;256(Suppl 1):i26-31. [DOI: 10.1007/s00406-006-10-4-4; PUBMED: 16977548]
- [117] Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). *European Archives of Psychiatry and Clinical Neuroscience* 2007;257(7):371-7. [DOI: 10.1007/s00406-007-0712-8; PUBMED: 17902010]
- [118] Stern A, Malik E, Pollak Y, Bonne O, Maeir A. The efficacy of computerized cognitive training in adults with ADHD: a randomized controlled trial. *Journal of Attention Disorders* 2016;20(12):991-1003. [DOI: 10.1177/1087054714529815; PUBMED: 24756172]
- [119] Sterne JAC, Egger M, Moher D, Boutron I, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- [120] Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database of Systematic Reviews* 2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2; PUBMED: 26599576]
- [121] ADD Forums. Attention deficit hyperactivity disorder support and information resources community. [www.addforums.com/forums/showthread.php?t=145273](http://www.addforums.com/forums/showthread.php?t=145273) (accessed 29 January 2017).
- [122] Suhr J, Zimak E, Buelow M, Fox L. Self-reported childhood attention-deficit/hyperactivity disorder symptoms are not specific to the disorder. *Comprehensive Psychiatry* 2009;50(3):269-75. [DOI: 10.1016/j.comppsy.2008.08.008; PUBMED: 19374973]
- [123] Surman CBH, Monuteaux MC, Petty CR, Faraone SV, Spencer TJ, Chu NF, et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. *The Journal of Clinical Psychiatry* 2010;71(12):1612-6. [DOI: 10.4088/JCP.09m05344pur; PMC3737773; PUBMED: 20816030]
- [124] Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. *Neuropharmacology* 2006;50(6):755-60. [DOI: 10.1016/j.neuropharm.2005.11.022; PUBMED: 16427661]
- [125] Swanson JM, Arnold LE, Molina BSG, Sibley MH, Hechtman LT, Hinshaw SP, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. *Journal of Child Psychology and Psychiatry* 2017;58(6):663-78. [DOI: 10.1111/jcpp.12684; PUBMED: 28295312]
- [126] Thapar A, Cooper M. Attention deficit hyperactivity disorder. *Lancet* 2016;387(10024):1240-50. [DOI: 10.1016/S0140-6736(15)00238-X; PUBMED: 26386541]
- [127] Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, et al. A critique of the international consensus statement on ADHD. *Clinical Child and Family Psychology Review* 2004;7(1):59-63; discussion 65-9. [PUBMED: 15119688]
- [128] Torres I, Gómez N, Colom F, Jiménez E, Bosch R, Bonnín CM, et al. Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. *Acta Psychiatrica Scandinavica* 2015;132(5):389-99. [DOI: 10.1111/acps.12426; PUBMED: 25900393]
- [129] Volkow ND, Swanson JM. Clinical practice: adult attention deficit-hyperactivity disorder. *New England Journal of Medicine* 2013;369(20):1935-44. [DOI: 10.1056/NEJMcp1212625; PMC4827421; PUBMED: 24224626]
- [130] Weibel S, Jermann F, Weiner L, Nicastro R, Ardu S, Pham E, et al. Insomnia in adult attention-deficit/hyperactivity disorder: a comparison with borderline personality disorder population in a clinical setting and control participants. *Comprehensive Psychiatry* 2017;76:119-28. [DOI: 10.1016/j.comppsy.2017.04.009; PUBMED: 28501733]
- [131] Weissenberger S, Ptacek R, Klicperova-Baker M, Erman A, Schonova K, Raboch J, et al. ADHD, lifestyles and comorbidities: a call for an holistic perspective - from medical to societal intervening factors. *Frontiers in Psychology* 2017;8:454. [DOI: 10.3389/fpsyg.2017.00454; PMC5382165; PUBMED: 28428763]
- [132] Wells BG, Gelenberg AJ. Chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of the antidepressant maprotiline hydrochloride. *Pharmacotherapy* 1981;1(2):121-39. [PUBMED: 6765485]

- [133] Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. *Journal of Clinical Psychopharmacology* 2004;24(1):30-5. [DOI: 10.1097/01.jcp.0000104907.75206.c2; PUBMED: 14709944]
- [134] Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?. *Journal of the American Academy of Child and Adolescent Psychiatry* 1987;26(5):676-86. [DOI: 10.1097/00004583-198709000-00011; PUBMED: 2889717]
- [135] Zheng G, Xue W, Wang P, Yang F, Li B, Li X, et al. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study. *Scientific Reports* 2016;6:26883. [DOI: 10.1038/srep26883; PMC4882549 ; PUBMED: 27230580]
- [136] Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: 10.1002/14651858.CD004795.pub4; PUBMED: 23744519]
- [137] Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. *Cochrane Database of Systematic Reviews* 2016, Issue 12. [DOI: 10.1002/14651858.CD007026.pub4; PUBMED: 27918088]
- [138] Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. *Cochrane Database of Systematic Reviews* 2017, Issue 4. [DOI: 10.1002/14651858.CD007026.pub5]
- [139] Ziganshina LE, Gamirova R, Abakumova T. Gabapentin monotherapy for epilepsy. *Cochrane Database of Systematic Reviews* 2017, Issue 6. [DOI: 10.1002/14651858.CD012710]